| 摘要 |
A pharmaceutical composition of solifenacin or salt thereof, which is stable and inhibited from decomposition with time for use in solid pharmaceutical preparation, comprising crystalline and amorphous solifenacin or a crystalline and amorphous salt thereof, whereby amorphous content is 77 % or less, together with an amorphization inhibitor. A substance having ethylene oxide chain, such as polyethylene glycol, is used as amorphization inhibitor. |
